Sage Rhino Capital’s Eli Lilly LLY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $2.42M | Buy |
2,014
+17
| +0.9% | +$17.4K | 0.39% | 60 |
|
|
2026
Q1 | $1.84M | Buy |
1,997
+1
| +0.1% | +$1.01K | 0.34% | 63 |
|
|
2025
Q4 | $2.15M | Sell |
1,996
-149
| -7% | -$142K | 0.4% | 53 |
|
|
2025
Q3 | $1.64M | Sell |
2,145
-6
| -0.3% | -$4.46K | 0.32% | 65 |
|
|
2025
Q2 | $1.68M | Buy |
2,151
+12
| +0.6% | +$9.32K | 0.35% | 59 |
|
|
2025
Q1 | $1.77M | Buy |
2,139
+10
| +0.5% | +$8.32K | 0.41% | 55 |
|
|
2024
Q4 | $1.64M | Sell |
2,129
-21
| -1% | -$17.4K | 0.36% | 57 |
|
|
2024
Q3 | $1.9M | Buy |
2,150
+7
| +0.3% | +$6.29K | 0.42% | 52 |
|
|
2024
Q2 | $1.94M | Buy |
2,143
+24
| +1% | +$19.2K | 0.46% | 51 |
|
|
2024
Q1 | $1.65M | Buy |
2,119
+16
| +0.8% | +$11.4K | 0.39% | 56 |
|
|
2023
Q4 | $1.23M | Sell |
2,103
-30
| -1% | -$17.5K | 0.31% | 64 |
|
|
2023
Q3 | $1.15M | Hold |
2,133
| – | – | 0.32% | 65 |
|
|
2023
Q2 | $1M | Sell |
2,133
-19
| -0.9% | -$7.97K | 0.28% | 73 |
|
|
2023
Q1 | $739K | Buy |
2,152
+38
| +2% | +$12.8K | 0.22% | 90 |
|
|
2022
Q4 | $773K | Sell |
2,114
-19
| -0.9% | -$6.74K | 0.25% | 80 |
|
|
2022
Q3 | $690K | Sell |
2,133
-17
| -0.8% | -$5.39K | 0.28% | 63 |
|
|
2022
Q2 | $697K | Buy |
2,150
+10
| +0.5% | +$3K | 0.27% | 66 |
|
|
2022
Q1 | $613K | Buy |
2,140
+2
| +0.1% | +$515 | 0.19% | 101 |
|
|
2021
Q4 | $591K | Sell |
2,138
-12
| -0.6% | -$3.04K | 0.17% | 108 |
|
|
2021
Q3 | $497K | Buy |
2,150
+63
| +3% | +$15.5K | 0.15% | 107 |
|
|
2021
Q2 | $479K | Buy |
2,087
+42
| +2% | +$8.44K | 0.14% | 111 |
|
|
2021
Q1 | $382K | Buy |
2,045
+29
| +1% | +$5.67K | 0.13% | 120 |
|
|
2020
Q4 | $340K | Buy |
2,016
+46
| +2% | +$6.87K | 0.13% | 116 |
|
|
2020
Q3 | $292K | Sell |
1,970
-75
| -4% | -$11.6K | 0.14% | 117 |
|
|
2020
Q2 | $336K | Buy |
2,045
+118
| +6% | +$18.1K | 0.18% | 103 |
|
|
2020
Q1 | $267K | Buy |
1,927
+23
| +1% | +$3.16K | 0.19% | 97 |
|
|
2019
Q4 | $263K | Sell |
1,904
-583
| -23% | -$67.6K | 0.15% | 119 |
|
|
2019
Q3 | $278K | Sell |
2,487
-79
| -3% | -$8.79K | 0.17% | 109 |
|
|
2019
Q2 | $284K | Sell |
2,566
-144
| -5% | -$17K | 0.18% | 104 |
|
|
2019
Q1 | $352K | Buy |
+2,710
| New | +$330K | 0.23% | 89 |
|
Other funds holding LLY
Sage Rhino Capital's LLY Position: Q2 2026 in Review
Sage Rhino Capital increased its Eli Lilly (LLY) stake by 0.85% in Q2 2026, buying an estimated $17.4K and bringing the position to 2,014 shares worth $2.42M. The position accounts for 0.39% of the portfolio, ranked #60.
Sage Rhino Capital first reported a position in LLY in Q1 2019 and has held it in 30 quarters since. 4,642 funds tracked by Wall St. Rank hold LLY as of Q2 2026.
- Sage Rhino Capital held 2,014 shares of Eli Lilly worth $2.42M as of Q2 2026.
- Sage Rhino Capital bought 17 Eli Lilly shares in Q2 2026, an estimated $17.4K.
- Eli Lilly made up 0.39% of Sage Rhino Capital's portfolio in Q2 2026, its #60 holding.
- Sage Rhino Capital first reported a position in Eli Lilly in Q1 2019 and has held it in 30 quarters since.
- 4,642 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.
Based on Sage Rhino Capital's 13F filing for Q2 2026, filed 3 Aug 2026.